Scientists develop novel chemical 'dye' to improve liver cancer imaging

May 2, 2017, National University of Singapore
A research team led by Assistant Professor Edward Chow (right), Principal Investigator from the Cancer Science Institute of Singapore at NUS and Department of Pharmacology at NUS Yong Loo Lin of Medicine, has developed a novel nanodiamond-based contrast agent – a chemical "dye" used to enhance the visibility of internal body structures in magnetic resonance imaging – that improves visualisation of liver cancer tumours. Credit: National University of Singapore

Scientists from the National University of Singapore (NUS) have developed a novel nanodiamond-based contrast agent—a chemical "dye" used to enhance the visibility of internal body structures in magnetic resonance imaging (MRI)—that improves visualisation of liver cancer tumours. Better and more sensitive imaging contributes towards detecting liver cancer and is crucial for planning for treatment.

MRI is a medical imaging technique commonly used for diagnosis and to track the progress of patients after treatment. Currently, there are two modes of MRI imaging, T1-weighted and T2-weighted imaging, and patients are often given contrast agents to improve imaging quality. However, each imaging mode requires a specific class of contrast agent which cannot be used together. This poses a greater challenge in the diagnosis of cancer, where T2-weighted imaging is still not considered reliable, and both T1- and T2-weighted imaging can be confounded by tumour vascularity.

A research team led by Assistant Professor Edward Chow, Principal Investigator from the Cancer Science Institute of Singapore at NUS and Department of Pharmacology at NUS Yong Loo Lin of Medicine, has developed a dual-mode contrast agent which enables clearer and more accurate of tumours to be obtained in both T1- and T2-weighted MRI scans, and with lower dosages of contrast agent.

Better tumour imaging using nanodiamond-based dual-mode contrast agent

The novel dual-mode contrast agent, which was developed using nanodiamonds in combination with a manganese base, provides greater imaging contrast than existing clinical agents which are used to improve quality of MRIs. The team also found that liver tumours that are unable to be visualised without contrast agents become readily visible even at low dosages of the novel compound.

The novel contrast agent (grey solution in larger tube), developed using nanodiamonds in combination with a manganese base, provides clearer and more accurate images of liver tumours at lower dosages. Credit: National University of Singapore

Contrast agents work by altering the magnetic properties of nearby , which enhances the quality of MR images. Nanodiamonds, which are carbon-based particles of two to eight nanometres in diameter, have unique chemical properties that allow them to attract water molecules. This enables them to promote proton exchange between water molecules and paramagnetic ions (i.e. contrast agents) that accumulate in tissues. As a result, T1 and T2 relaxation is enhanced, giving better quality images. This is unlike existing nanotechnology-based approaches, where nanomaterials are used to improve delivery of paramagnetic ions to specific tumour sites.

"Our experiments suggest that our dual-mode contrast agent holds great promise in improving imaging for liver cancer. We are hopeful that this advancement in nanomedicine will lead to safer and more accurate diagnosis of . Moving forward, we plan to conduct further prepreclinical safety studies for our agents, with the end goal being clinical implementation. We are also looking into using our to improve imaging for glioma and ovarian cancer," said Asst Prof Chow.

Explore further: Using sugar to detect malignant tumours

More information: Weixin Hou et al. Nanodiamond–Manganese dual mode MRI contrast agents for enhanced liver tumor detection, Nanomedicine: Nanotechnology, Biology and Medicine (2017). DOI: 10.1016/j.nano.2016.12.013

Related Stories

Using sugar to detect malignant tumours

February 22, 2016
Ordinary sugar could become a contrast agent of the future for use in magnetic resonance tomography examinations of tumours. Malignant tumours show higher sugar consumption than surrounding tissue.

Sharper imaging would promote earlier diagnosis of malignancies

November 18, 2016
A common chemical element embedded in a tiny bubble of fat has the potential to advance cancer imaging. In a study of pet dogs that were biopsied for cancer, a new contrast agent used in CT imaging allowed veterinarians to ...

Multiple sclerosis: Reduced levels of contrast agent deposits in the brain

December 12, 2016
Gadolinium, one of the rare earth elements, is used as a contrast agent that enhances the quality of MRI examinations of internal organs and tissues. Researchers from Charité - Universitätsmedizin Berlin (NeuroCure Clinical ...

Recommended for you

New therapeutic gel shows promise against cancerous tumors

February 21, 2018
Scientists at the UNC School of Medicine and NC State have created an injectable gel-like scaffold that can hold combination chemo-immunotherapeutic drugs and deliver them locally to tumors in a sequential manner. The results ...

Five novel genetic changes linked to pancreatic cancer risk

February 21, 2018
In what is believed to be the largest pancreatic cancer genome-wide association study to date, researchers at the Johns Hopkins Kimmel Cancer Center and the National Cancer Institute, and collaborators from over 80 other ...

Kinase inhibitor larotrectinib shows durable anti-tumor abilities

February 21, 2018
Three simultaneous safety and efficacy studies of the drug larotrectinib reported an overall response rate of 75 percent for patients ages four months to 76 years with 17 different cancer diagnoses. All patients had tumors ...

Similarities found in cancer initiation in kidney, liver, stomach, pancreas

February 21, 2018
Recent research at Washington University School of Medicine in St. Louis demonstrated that mature cells in the stomach sometimes revert back to behaving like rapidly dividing stem cells. Now, the researchers have found that ...

Research could change how doctors treat leukemia and other cancers fed by fat

February 21, 2018
Obesity and cancer risk have a mysterious relationship, with obesity increasing the risk for 13 types of cancer. For some cancers—including pediatric cancers—obesity affects survival rates, which are lower for people ...

New technique predicts gene resistance to cancer treatments

February 21, 2018
Yale School of Public Health researchers have developed a new method to predict likely resistance paths to cancer therapeutics, and a methodology to apply it to one of the most frequent cancer-causing genes.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.